Illinois Municipal Retirement Fund Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Illinois Municipal Retirement Fund boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 67.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,665 shares of the biopharmaceutical company's stock after purchasing an additional 25,298 shares during the quarter. Illinois Municipal Retirement Fund's holdings in Alnylam Pharmaceuticals were worth $14,746,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $61,160,000. Strategic Financial Concepts LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $41,529,000. Eventide Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 157.9% in the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock valued at $61,698,000 after purchasing an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after purchasing an additional 135,829 shares during the period. Finally, Telemark Asset Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $27,503,000. Institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company's stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,986 shares of company stock valued at $20,397,849 over the last quarter. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ALNY shares. Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Raymond James upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a report on Friday, November 1st. Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Barclays upped their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $304.26.

Alnylam Pharmaceuticals Stock Up 4.1 %

Shares of ALNY traded up $9.65 during midday trading on Friday, hitting $246.75. 1,178,627 shares of the company's stock traded hands, compared to its average volume of 731,883. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm's fifty day moving average is $254.30 and its 200-day moving average is $262.42. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $31.94 billion, a price-to-earnings ratio of -113.71 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.